The Management Board of Qumak S.A. (hereinafter referred to as the "Company") informs that on August 9, 2018, Annex 1 was signed (hereinafter referred to as "Annex") to the consortium agreement concluded with Engave Services Sp. z o.o. determining the parties' remuneration for the performance of the subject of the contract, which the parties have concluded the contract for.
The consortium agreement was concluded between Engave Services Sp. z o.o. (Consortium leader) and Qumak S.A. (hereinafter referred to as the "Parties") on 20 February 2018 and its subject was the cooperation of the Parties aimed at making an offer in the public procurement procedure conducted by the National Health Fund under an open tender, the subject of which is the delivery of 4 servers database for the National Health Fund, and in the case of selecting the offer as the most advantageous - execution of the order resulting from the settlement of this tender.
As a result of the selection of the consortium's offer as the most advantageous, on June 26, 2018, the consortium leader concluded an agreement with the National Health Fund for the supply of 4 server units (hereinafter referred to as the "Order"). The agreement defines the total remuneration for the implementation of the subject of the contract in the amount of PLN 11.057.700 gross and the term of the Contract, which is to be performed within 7 weeks from the date of conclusion of the contract.
In turn, in the Annex to the consortium agreement, the Parties have clarified the mutual rights, obligations and responsibilities of the Parties and specified their remuneration for the implementation of the Order, and also undertook to carry out the Order together.
Due to the implementation of the Order, the Company will receive a remuneration of PLN 8.395.977.54 gross.
The Annex establishes responsibility for non-execution of ranges assigned to individual consortium members, setting it to the maximum amount of remuneration of each of the consortium members.
Conclusion of the Annex to the contract, specifying precisely the remuneration for Qumak S.A. for the execution of the Order, it was considered significant for the Company due to its value and the expected impact on the Company's revenue.
Article 17 paragraph 1 MAR - confidential information.
Source: company website, investor relations, current and periodic reports.